The rate of ypCR in advanced rectal cancer was about 10%. This phenomenon seems to occur in tumours with a low risk of metastasizing. The contribution of neoadjuvant therapy to ypCR on survival was small or absent.
No takes yet. Share an insight, caveat, or question.
Wasmuth et al. (2015) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: